المؤلفون: CRISCI, ISABELLA, Aragona, Michele, Politi, Konstantina Savvina, DANIELE, GIUSEPPE, DEL PRATO, STEFANO

المساهمون: Crisci, Isabella, Aragona, Michele, Politi, Konstantina Savvina, Daniele, Giuseppe, DEL PRATO, Stefano

مصطلحات موضوعية: Continuous glucose monitoring, Glycemic variability, Insulin pump therapy, Liraglutide, Type 1 diabete, Adult, Aged, Area Under Curve, Blood Glucose, Body Mass Index, C-Peptide, Diabetes Mellitus, Type 1, Female, Glucagon-Like Peptide-1 Receptor, Hemoglobin A, Glycosylated, Human, Hypoglycemia, Hypoglycemic Agent, Male, Middle Aged, Endocrinology, Internal Medicine, Diabetes and Metabolism

الوصف: Aims: To test potential efficacy of liraglutide, a GLP-1 receptor agonist, in subjects with type 1 diabetes (T1DM). Methods: We have recruited nine T1DM patients (age 40.1±6.4years, duration of diabetes 19.2±8.8years, BMI 24.3±3.5kg/m2, HbA1c 8.2±1.0%–66±11mmol/mol, daily insulin dose: 0.6±0.1IU/kg) on continuous subcutaneous insulin therapy with undetectable C-peptide. In addition to existing treatment was administered in single-blind (a) therapy subcutaneously with 0.1ml of saline solution for 3days and (b) 0.1ml of liraglutide (0.6mg/day) for a further 3days with daily glucose excursions recorded by continuous glucose monitoring. Results: Adding liraglutide resulted in a significant reduction in mean blood glucose (138±29 vs. 163±29mg/dl, p<0.0001) and standard deviation (42±9 vs. 60±15mg/dl, p<0.0001). The area under the curve (AUC) for blood glucose >140mg/dl was also significantly reduced (22.2±16.4 vs. 41.1±19.7mg/dlh, p<0.05) with no difference in AUC for blood glucose <70mg/dl (liraglutide 0.7±0.9mg/dlh; placebo: 0.8±1.4mg/dlh, p=NS). Finally, adding liraglutide reduced daily insulin requirement (37.5±17.2 vs. 42.9±22.4 UI/day, p<0.01). Conclusions: Short-term treatment with liraglutide, in T1DM, reduces average blood glucose, blood glucose variability and daily insulin requirement without increasing risk of hypoglycemia.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/26293127; info:eu-repo/semantics/altIdentifier/wos/WOS:000363950500014; volume:52; issue:6; firstpage:1129; lastpage:1133; numberofpages:5; journal:ACTA DIABETOLOGICA; http://hdl.handle.net/11568/763653Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84945461146; link.springer.de/link/service/journals/00592/index.htm

الإتاحة: https://doi.org/10.1007/s00592-015-0800-6Test
http://hdl.handle.net/11568/763653Test

المؤلفون: Peeters, Stijn A., Engelen, Lian, Buijs, Jacqueline, Chaturvedi, Nish, Fuller, John H., Schalkwijk, Casper G., Stehouwer, Coen D, Karamanos, B., Kofinis, A., Petrou, K., Giorgino, F., Picca, G., Angarano, A., Null, de P.e.r.g.o.l.a. G., Laviola, L., Giorgino, R., Ionescu Tirgoviste, C., Coszma, A., Guja, C., Songini, M., Casu, A., Pedron, M., Pintus, S., Fossarello, M., Ferriss, J. B., Grealy, G., O'Keefe, D., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Koivisto, V. A., Idzior Walus, B., Sieradzki, J., Cyganek, K., Solnica, B., Lemkes, H. H. P. J., Lemkes Stuffken, J. C., Nunes Correa, J., Rogado, M. C., Gardete Correia, L., Cardoso, M. C., Silva, A., Boavida, J., Machado Sa Marques, M., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Mangili, R., Asnaghi, V., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, M., Verier Mine, O., Fallas, P., Fallas, M. C., Fuller, J. H., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D'Alessandro, V., Cagini, C., Bottini, P., Reboldi, G. P., Navalesi, R., Bandinelli, S., Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, A., Minnella, A., Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Borra, M., Cavallo Perin, P., Giunti, S., Grassi, G., Pagano, G. F., Porta, M., Sivieri, R., Vitelli, F., Veglio, M., Papazoglou, N., Manes, G., Muggeo, M., Iagulli, M., Cacciatori, V., Cattedra di Malattie del Metabolismo, V., Irsigler, K., Abrahamian, H., Walford, S., Sinclair, J., Hughes, S., Mclelland, V., Ward, J., Roglic, G., Metelko, Z., Pepeonik, Z. R., PENNO, GIUSEPPE, MICCOLI, ROBERTO, NANNIPIERI, MONICA

المساهمون: Peeters, Stijn A., Engelen, Lian, Buijs, Jacqueline, Chaturvedi, Nish, Fuller, John H., Schalkwijk, Casper G., Stehouwer, Coen D, Karamanos, B., Kofinis, A., Petrou, K., Giorgino, F., Picca, G., Angarano, A., Null, de P. e. r. g. o. l. a. G., Laviola, L., Giorgino, R., Ionescu Tirgoviste, C., Coszma, A., Guja, C., Songini, M., Casu, A., Pedron, M., Pintus, S., Fossarello, M., Ferriss, J. B., Grealy, G., O'Keefe, D., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Koivisto, V. A., Idzior Walus, B., Sieradzki, J., Cyganek, K., Solnica, B., Lemkes, H. H. P. J., Lemkes Stuffken, J. C., Nunes Correa, J., Rogado, M. C., Gardete Correia, L., Cardoso, M. C., Silva, A., Boavida, J., Machado Sa Marques, M., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Mangili, R., Asnaghi, V., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, M., Verier Mine, O., Fallas, P., Fallas, M. C., Fuller, J. H., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D'Alessandro, V., Cagini, C., Bottini, P., Reboldi, G. P., Navalesi, R., Penno, Giuseppe, Bandinelli, S., Miccoli, Roberto, Nannipieri, Monica, Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, A., Minnella, A., Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Borra, M., Cavallo Perin, P., Giunti, S., Grassi, G., Pagano, G. F., Porta, M., Sivieri, R., Vitelli, F., Veglio, M., Papazoglou, N., Manes, G.

مصطلحات موضوعية: Albuminuria, Cardiovascular disease, Matrix metalloproteinase, Retinopathy, Tissue inhibitor of metalloproteinase, Type 1 diabete, Adult, Biomarker, Cohort Studie, Cross-Sectional Studie, Diabetes Complication, Diabetes Mellitus, Type 1, Europe, Female, Human, Male, Matrix Metalloproteinase 10, Matrix Metalloproteinase 2, Matrix Metalloproteinase 3, Middle Aged, Prospective Studie, Tissue Inhibitor of Metalloproteinase-1, Vascular Disease, Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine

الوصف: Impaired regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in patients with type 1 diabetes. We investigated associations between plasma MMP-1, -2, -3, -9, -10 and TIMP-1, and cardiovascular disease (CVD) or microvascular complications in type 1 diabetic patients. We also evaluated to which extent these associations could be explained by low-grade inflammation (LGI) or endothelial dysfunction (ED). Methods: 493 type 1 diabetes patients (39.5 ± 9.9 years old, 51% men) from the EURODIAB Prospective Complications Study were included. Linear regression analysis was applied to investigate differences in plasma levels of MMP-1, -2, -3, -9, -10, and TIMP-1 between patients with and without CVD, albuminuria or retinopathy. All analyses were adjusted for age, sex, duration of diabetes, Hba1c and additionally for other cardiovascular risk factors including LGI and ED. Results: Patients with CVD (n = 118) showed significantly higher levels of TIMP-1 [β = 0.32 SD (95%CI: 0.12; 0.52)], but not of MMPs, than patients without CVD (n = 375). Higher plasma levels of MMP-2, MMP-3, MMP-10 and TIMP-1 were associated with higher levels of albuminuria (p-trends were 0.028, 0.004, 0.005 and 0.001, respectively). Severity of retinopathy was significantly associated with higher levels of MMP-2 (p-trend = 0.017). These associations remained significant after further adjustment for markers of LGI and ED. Conclusions: These data support the hypothesis that impaired regulation of matrix remodeling by actions of MMP-2, -3 and-10 and TIMP-1 contributes to the pathogenesis of vascular complications in type 1 diabetes.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/25848912; volume:14; issue:1; firstpage:31; journal:CARDIOVASCULAR DIABETOLOGY; http://hdl.handle.net/11568/838374Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84925234995; http://www.cardiab.com/homeTest/

الإتاحة: https://doi.org/10.1186/s12933-015-0195-2Test
http://hdl.handle.net/11568/838374Test
http://www.cardiab.com/homeTest/

المؤلفون: Bruttomesso, Daniela, Laviola, Luigi, Lepore, Giuseppe, Bonfanti, Riccardo, Bozzetto, Lutgarda, Corsi, Andrea, Di Blasi, Vincenzo, Girelli, Angela, Grassi, Giorgio, Iafusco, Dario, Rabbone, Ivana, Schiaffini, Riccardo, DEL PRATO, STEFANO

المساهمون: Bruttomesso, Daniela, Laviola, Luigi, Lepore, Giuseppe, Bonfanti, Riccardo, Bozzetto, Lutgarda, Corsi, Andrea, Di Blasi, Vincenzo, Girelli, Angela, Grassi, Giorgio, Iafusco, Dario, Rabbone, Ivana, Schiaffini, Riccardo, DEL PRATO, Stefano

مصطلحات موضوعية: Adult, Blood Glucose, Child, Cost-Benefit Analysi, Diabetes Mellitus, Type 1, Female, Guideline Adherence, Health Care Survey, Human, Hypoglycemic Agent, Infusions, Subcutaneou, Insulin, Italy, Male, Practice Patterns, Physicians', Surveys and Questionnaire, Endocrinology, Diabetes and Metabolism, Medical Laboratory Technology, Medicine (all)

الوصف: Background: Continuous subcutaneous insulin infusion (CSII) is increasing worldwide, mostly because of improved technology. The aim of this study was to evaluate the current status of CSII in Italy. Materials and Methods: Physicians from 272 diabetes centers received a questionnaire investigating clinical features, pump technology, and management of patients on CSII. Results: Two hundred seventeen centers (79.8%) joined the study and, by the end of April 2013, gave information about 10,152 patients treated with CSII: 98.2% with type 1 diabetes mellitus, 81.4% adults, 57% female, and 61% with a conventional pump versus 39% with a sensor-augmented pump. CSII advanced functions were used by 68% of patients, and glucose sensors were used 12 days per month on average. Fifty-eight percent of diabetes centers had more than 20 patients on CSII, but there were differences among centers and among regions. The main indication for CSII was poor glucose control. Dropout was mainly due to pump wearability or nonoptimal glycemic control. Twenty-four hour assistance was guaranteed in 81% of centers. A full diabetes team (physician+nurse+dietician+psychologist) was available in 23% of adult-care diabetes centers and in 53% of pediatric diabetes units. Conclusions: CSII keeps increasing in Italy. More work is needed to ensure uniform treatment strategies throughout the country and to improve pump use.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/25479035; info:eu-repo/semantics/altIdentifier/wos/WOS:000349009600005; volume:17; issue:2; firstpage:96; lastpage:104; numberofpages:9; journal:DIABETES TECHNOLOGY & THERAPEUTICS; http://hdl.handle.net/11568/837992Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84922440593; www.liebertonline.com/dia

الإتاحة: https://doi.org/10.1089/dia.2014.0242Test
http://hdl.handle.net/11568/837992Test

المؤلفون: MASI, STEFANO, Gkranias, Nikolaos, Li, Kawa, Salpea, Klelia D., Parkar, Mohamed, Orlandi, Marco, Suvan, Jean E., Eng, Heng L., Patel, Kalpesh, Darbar, Ulpee, Donos, Nikos, Deanfield, John E., Hurel, Steve, Humphries, Steve E., D'Aiuto, Francesco, TADDEI, STEFANO

المساهمون: Masi, Stefano, Gkranias, Nikolao, Li, Kawa, Salpea, Klelia D., Parkar, Mohamed, Orlandi, Marco, Suvan, Jean E., Eng, Heng L., Taddei, Stefano, Patel, Kalpesh, Darbar, Ulpee, Donos, Niko, Deanfield, John E., Hurel, Steve, Humphries, Steve E., D'Aiuto, Francesco

مصطلحات موضوعية: Adult, Aged, Cross-Sectional Studie, Diabetes Mellitus, Type 1, Type 2, Endotoxemia, Female, Human, Leukocyte, Male, Middle Aged, Periodontiti, Real-Time Polymerase Chain Reaction, Telomere Shortening, Internal Medicine, Endocrinology, Diabetes and Metabolism, Advanced and Specialized Nursing

الوصف: OBJECTIVE: Shortened leukocyte telomere length (LTL) and diagnosis of periodontitis are associated with an increased risk of complications and mortality in diabetes. This study investigated the association between LTL, endotoxemia, and severity of periodontitis in a large cohort of people with diabetes. RESEARCH DESIGN AND METHODS: Six hundred thirty individuals (371 with type 2 and 259 with type 1 diabetes) were recruited from the University College Hospital in London, U.K. During a baseline visit, blood was collected for standard biochemical tests and DNA extraction, while a dental examination was performed to determine diagnosis and extent of periodontitis. LTLwas measured by real-time PCR, and endotoxemia was assessed by the limulus amoebocyte lysate method. RESULTS: Two hundred fifty-five individuals were diagnosed with gingivitis, 327 with periodontitis (114 with moderate and 213 with severe disease), and 48 with edentulous. Diagnosis of periodontitis was associated with shorter LTL (P = 0.04). A negative association between LTL and endotoxemia was found in the severe periodontitis and type 2 diabetes groups (P = 0.01 for both). Shorter LTL was associated with increased extent of periodontitis (P = 0.01) and increased insulin resistance (homeostatic model assessment). Multiple adjustments for biochemical, anthropometric, and medication-use variables did not affect the results. CONCLUSIONS: LTL is associated with endotoxemia and diagnosis of periodontitis in people with diabetes. LTL shortening might represent a novel biological pathway accounting for previous epidemiological data that documented higher prevalence of diabetes and its complications in people with periodontitis and vice versa. © 2014 by the American Diabetes Association.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/24652728; info:eu-repo/semantics/altIdentifier/wos/WOS:000333414700048; volume:37; issue:4; firstpage:1140; lastpage:1147; numberofpages:8; journal:DIABETES CARE; http://hdl.handle.net/11568/782539Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84897880311; http://care.diabetesjournals.org/content/37/4/1140.full.pdfTest

الإتاحة: https://doi.org/10.2337/dc13-2106Test
http://hdl.handle.net/11568/782539Test
http://care.diabetesjournals.org/content/37/4/1140.full.pdfTest